Company intelligence / Profile preview

Peptilogics

Pittsburgh, Pennsylvania, United Statespeptilogics.com ↗

Ownership: Private
Employees: ~30
Development stage: Phase 1

Overview

Peptilogics has advanced its lead candidate, PLG0206—a novel broad-spectrum anti-infective peptide—into clinical trials for prosthetic joint infection. The company leverages its proprietary Nautilus™ AI platform to accelerate the discovery and optimization of new peptide therapeutics targeting challenging diseases. No detailed published clinical results are available in the provided sources.

Therapeutic areas: OtherInfectious Diseases
Modalities: Peptide therapeuticsAI-driven peptide design
Industry: Biotech

Drug pipeline

6 assets

zaloganan

5 more assets in the full pipeline.

Request access →

Partnerships

Orion Biotechnology (strategic research collaboration on GPCR drug discovery using AI platforms)

Beyond the preview

Go deeper on Peptilogics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Peptilogics.

Explore the full profile